EPIC Biophotonics Symposium and Exhibition 26-27 November 2015 | Berlin, Germany
Total Page:16
File Type:pdf, Size:1020Kb
www.epic-assoc.com/epic-biophotonics-symposium-and-exhibition Talks by medical doctors: 15 minutes + 5 minutes Q&A Talks by companies, universities and research organizations: 10 minutes + 5 minutes Q&A Please note that timing is strictly respected at EPIC meetings. No company pitch, focus on technology. This is an EPIC technology workshop fostering exchange among actors of the value chain. Prior to the event, a list of participants including biography + picture of each attend and company description will be shared. The event is limited to 75 attendees to ensure efficient networking. 25 NOVEMBER 2015 EPIC members, EPIC committee, and medical doctors only (free of charge, registration required) 20:00 Dinner – Location to be announced. 26 NOVEMBER 2015 EPIC members, EPIC committee, and medical doctors only (free of charge, registration required) 08:30 Welcome Coffee 09:00 Introduction to Elisabeth Klinik - Zentrum Lasermedizin by Prof. Dr.med. H.-Peter Berlien 09:15 Medical doctor presentation + discussion 10:00 Coffee Break 10:30 Medical doctor presentation + discussion 11:15 Departure to Messe Berlin for EPIC Workshop (bus / car / public transport) 12:00 REGISTRATION / SNACKS / NETWORKING MARKETPLACE Session 1: Photonics-enabled in-vivo Imaging and Spectroscopy in Oncology Cellular microscopy techniques (confocal, spectroscopy, Raman, etc.) are already available to provide accurate characterization of tissues but the true challenge now is to bring these microscopic optical approaches into endoscopic instruments. This in vivo microscopy will contribute significantly to improve the diagnosis of several pathologies in the clinic. Topic 1 : Label-free Imaging Modalities for in-situ resection monitoring 13:00 EPIC Welcome, Carlos Lee, Director General 13:10 “Application of spectroscopic methods for the prevention of side effects on patients during chemotherapy” by Prof. Dr. Dr.-Ing Juergen Lademann, M. Darvin, H. Richter, A. Patzelt, M. Meinke, S. Jung. Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology, Venerology and Allergology, Charité – Universitätsmedizin Berlin, Berlin, Germany Although chemotherapeutics for cancer treatment are becoming increasingly efficient these days, they often cause severe dermal side effects. Systemically applied doxorubicin is known for inducing free radicals, which lead to the development of the hand-foot syndrome. This syndrome manifests itself through skin irritations via blistering to open wounds. As doxorubicin exhibits a fluorescence signal in the 520-600 nm region if excited at 488 nm, the doxorubicin’s leakage onto the skin surface could be analysed. It was found that part of the doxorubicin is ejected with the sweat onto the skin surface, where it spreads and penetrates into the skin like topically applied. This process is prominent especially in the palmar and plantar region where the density of sweat glands is highest. By topical application of antioxidants the doxorubicin could be prevented from inducing free radicals in the skin and consequently the hand-foot syndrome. 13:30 “Real-time multispectral imaging for biomedical applications” by Dr. Nikolaos Deliolanis, Group Leader, Fraunhofer IPA-PAMB Multispectral (MS) imaging of tissue can reveal anatomical, functional and pathological information by identifying concentrations of absorbers like oxy- and deoxy-hemoglobin and, additionally, multiple intrinsic fluorochromes or externally administered probes. State of the art MS imaging systems are limited: they can image only one fluorochrome, and not simultaneously with color images. We present an imaging platform based on a combined approach of temporal and spectral multiplexing that acquires MS fluorescence and reflectance images over the entire VIS/NIR spectrum without spectral gaps and unmixes the images to 6 fluorescence and 6 reflectance components. It can be directly adapted to existing systems like surgical microscopes or rigid endoscopes. We present results from preclinical experiments of fluorescence guided in-vivo tumor resection. 13:45 “OCT: an excellent match between what we have and what we want for the next generation medicine, applied to cancer” by Frans Dhaenens, Clinical Research Consultant, Agfa HealthCare The current trend of "precision medicine" points towards diagnostic and therapeutic genetic- determined biological processes with a personal basis. The medical model shifts towards sensitive and specific "point-of-care" detection technologies often multiplexed, generating huge datasets, which can be analysed in a meaningful way because they obey well established laws of physics giving sight on "quantum-biologics". Photonic imaging methods have the potential to span the classic divide between macro-imaging and histopathology. When offered at an attractive cost, photonics are accepted easily in a rather conservative daily workflow. The approach of photonic imaging to the growing cancer problem is demonstrative for its potential in medicine. 14:00 “Optical in vivo detection of cancer by Raman microspectroscopy” by Dr. Oliver Duehr, Senior Sales Engineer, Ocean Optics At present the success of a standard cancer treatment is investigated by biopsy and laboratory analysis. With the demonstrated in vivo Raman microspectroscopy it is possible to accelerate this process down to a few seconds to get information about the success of the cancer treatment and to distinguish between either vital or necrotic tissue by Raman spectra and assignment of the Raman spectral clusters. Although a classification model for the spectral data is used, the discrimination of necrotic and vital tissue yield an accuracy of 100%. The results makes Raman spectroscopy a powerful candidate for in vivo carcinogenic tissue analysis. 14:15 “The future of bio-optics in peri-operative surgical oncology” by Tim Clay, Associate Director, Global Medtech, Cambridge Consultants Significant advances have been achieved in real-time optical imaging strategies for intraoperative tumour detection and margin assessment. Optical imaging holds promise in achieving the highest percentage of negative surgical margins and in early detection of micrometastastic disease over the next decade. Currently the use of imaging modalities for guidance during surgical interventions has been limited to incidental use of intraoperative X-ray fluoroscopy and ultrasonography. However, there is a rapidly developing landscape for novel optical technologies, which will uncover the detailed micro-structure of tumour pathologies in situ and provide surgeons with new tools and techniques for successful patient treatment. We intend to provide a review of such techniques and weigh up the significance of such technologies. 14:30 COFFEE BREAK & NETWORKING IN MARKETPLACE Topic 2 : Progress in Fiber Optics for Minimally Invasive Surgery & Diagnostic 15:00 “In vivo study for the discrimination of cancerous and normal skin using fibre probe-based Raman spectroscopy” by Asst. Prof. Martina C. Meinke1, J. Schleusener 2, P. Gluszczynska 2, C.Reble1,2, I. Gersonde 2, J. Helfmann 2, JW Fluhr1, J. Lademann , H. Röwert 1, A. Patzelt1 1 Department of Dermatology, Venerology and Allergology, Charité – Universitätsmedizin Berlin, Germany 2 Laser- und Medizin-Technolgie GmbH Berlin, Berlin, Germany The application of fiber-coupled Raman probes for the discrimination of cancerous and normal skin has the advantage of a noninvasive in vivo application, easy clinical handling, and access to the majority of body sites, which would otherwise be limited by stationary Raman microscopes. In this in vivo clinical evaluation, the probe design is optimized for epithelial sensitivity, whereby a large part of the detected signal originates from within the epidermal layer’s depth down to the basal membrane where early stages of skin cancer develop. 15:30 Bioresorbable optical fibres: status and perspectives” by Daniel Milanese, Associate Professor, Politecnico di Torino Typically, the implementation of optical fibres to the biomedical field have foremost focused on the bio-compatibility of the fibre material. The development of bioresorbable optical fibres could pave the way to novel biomedical devices that combine several health diagnostic functionalities in compact format. The main types of currently available bioresorbable optical fibres will be reviewed together with their advantage and their range of applications. 15:45 "Specialty Optical Fibers Make Surgery Less Invasive" by Chris Emslie, CEO, Fibercore The use of specialised coatings, appropriately selected and processed enable fibers to survive multiple cycles of autoclave sterilisation. Careful matching and tight control of optical parameters facilitate optical coherence tomography (OCT) used in non-contact surface profiling for opthalmology as well as the precise navigation of blood-vessels to enable the safe and even de-skilled insertion of guide-wires. The incorporation of minute, intrinsic sensors into probes make the measurement of blood-flow and even gas analysis possible. The next generation of catheters and guide-wires, combining multi-core and FBG technologies may even render X-ray obsolete in many procedures by providing real-time information of the exact shape of the probe. 16:00 "Fiber spectroscopy for biophotonics - methods & sensors for promising applications" by Dr. Viacheslav Artyushenko, President, art photonics Spectral fiber sensors development described to detect tumor margins – due to the need to reduce 30% of incomplete tumor removal in surgery. Comparison of